Australia in front on KEYTRUDA

As patients and clinicians celebrate the PBS listing of MSD's KEYTRUDA (pembrolizumab) for advanced melanoma, an analysis by MAESTrO shows Australia well in front of other HTA markets when it comes to funding access to the anti-PD-1 therapy. …